Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 137Breast Neoplasms 10Neoplasm Metastasis 8Neoplasms 5Bulbo-Spinal Atrophy, X-Linked 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Osteoporosis 2Lower Urinary Tract Symptoms 2Hirsutism 2Thrombocytosis 1Stage I Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Sexual Dysfunction, Physiological 1Recurrence 1Primary Myelofibrosis 1Primary Dysautonomias 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

bicalutamide 2mirabegron 1Transcutaneous Electric Nerve Stimulation 1Tamoxifen 1Sugars 1Sodium Chloride 1Pentosan Sulfuric Polyester 1Dutasteride 1Doxazosin 1Diclofenac 1Cystoscopy 1Celecoxib 1Catheters, Indwelling 1Capsules 1Botulinum Toxins, Type A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lower Urinary Tract Symptoms × bicalutamide × Clear all
NCT04284761 2024-06-24

Biolen-PC

Alessa Therapeutics Inc.

Phase 1 Completed
17 enrolled

Lower Urinary Tract Symptoms

NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

CHU de Quebec-Universite Laval

Phase 2 Completed
60 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡